ClinicalTrials.gg
Not yet recruitingNCT07940712CARTSUpdated Nov 17, 2026

Cognitive Augmentation, Remediation, and TDCS for Schizophrenia

An interventional study of High-definition transcranial direct current stimulation and Cognitive remediation therapy in Schizophrenia / Schizoaffective Disorder, sponsored by Beth Israel Deaconess Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Schizophrenia by Beth Israel Deaconess Medical Center — 3 open to participants now, 4 under way, 1 of them phase 3. Schizophrenia · Beth Israel Deaconess Medical Center.

Planned enrollment
12th of 15
10 · median 20
Started
2026
the only one that year
No phase
10 of 16
2 open now
Registered
16th of 16
by date

Among the 16 studies in Schizophrenia by Beth Israel Deaconess Medical Center, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 16th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 16 studies in Schizophrenia by Beth Israel Deaconess Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Schizophrenia by Beth Israel Deaconess Medical Center, or all of them as a file.
02

Study summary

Schizophrenia-spectrum disorders (SSDs; schizophrenia, schizoaffective disorder, etc.) are among the most disabling and costly conditions globally. Most SSD medications treat symptoms like hallucinations and delusions, but cognitive symptoms, or problems with thinking, memory, and problem solving, remain untreated by medication. Other developing treatments for these symptoms include noninvasive stimulation of cognitive brain regions and behavioral therapies involving mental skill-building activities. While both of these treatments appear to improve cognitive symptoms, effects are inconsistent depending on specific details of the trial. Growing evidence suggests that using these therapies together could lead to larger, clinically meaningful effects. Still, prior combined therapy trials use simplified versions of the behavioral therapy, omitting the guidance of a therapist to engage and challenge the participant. These previous trials show some evidence for beneficial effects, particularly in working memory, but the omission of a therapist could limit effects. This study will be the first to test if using a comprehensive, therapist-guided behavioral therapy can amplify the effects of noninvasive brain stimulation (NIBS) to reduce cognitive symptoms and change brain activity in SSDs. We will conduct a small pilot study to gather preliminary evidence for this combined therapy using 10 participants split into 2 groups. One group will receive NIBS and comprehensive cognitive therapy (NIBS+) while the other receives NIBS and performs quizzes without the guidance of a therapist (NIBS-). Participants will receive therapies for 10 days over 2 weeks with 2 hours of therapy per day. We will compare interventions through the following aims. Aim 1 will examine changes in brain connections after NIBS+ and NIBS-. We will collect data from electrical brain recordings (electroencephalography/EEG) before and after interventions. We expect that connections between cognitive brain regions will be most strengthened by NIBS+ compared to NIBS-. Aim 2 will investigate what kind of cognitive symptoms are affected by NIBS+ and NIBS-. We will perform cognitive tests before and after the interventions. We expect that all cognitive symptoms (memory, motor speed, language skills, attention, processing speed, and planning abilities) will be most improved by NIBS+ compared to NIBS-, but that the largest improvements will be in short-term, active memory skills ("working memory"). We will also investigate if there is a relationship between the changes in brain connections and cognitive improvements.

This preliminary study will provide early evidence that the effects of noninvasive brain stimulation can be strengthened by a structured, therapist-guided behavioral therapy for cognitive symptoms. This will support the development of a new, combined therapy for untreated cognitive symptoms in schizophrenia-spectrum disorders. We will use findings of this study to support a trial proposal to the National Institute of Mental Health to test this therapy in a larger group of individuals.

03

Conditions studied

  • Schizophrenia / Schizoaffective Disorder

Keywords

  • brain stimulation
  • tDCS
  • cognitive remediation
  • schizophrenia
  • cognitive disability
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
  • Proficient in English
  • IQ >= 80

Exclusion criteria

Exclusion Criteria:

  • Major neurological conditions
  • Implanted devices in the body or metal in the head
  • Changes to relevant medications within 1 month of enrollment
  • Pregnancy or breastfeeding
  • Moderate to severe DSM V substance use disorder
  • Clinical instability including recent or severe suicidal ideation or actions
  • Positive urine drug screen for illicit substances
  • Skin allergy to lidocaine or electrolyte gel
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    NIBS+

    Combined transcranial direct current stimulation and cognitive remediation therapy (both active)

    Device: High-definition transcranial direct current stimulation · Behavioral: Cognitive remediation therapy

  • Active comparator
    NIBS-

    Transcranial direct current stimulation and sham cognitive remediation therapy (active tDCS and sham CRT)

    Device: High-definition transcranial direct current stimulation · Behavioral: Sham cognitive remediation therapy

Interventions

  • DeviceHigh-definition transcranial direct current stimulation

    Active HD-tDCS delivered to the left dorsolateral prefrontal cortex

    Also known as: HD-tDCS

  • BehavioralCognitive remediation therapy

    Active cognitive remediation therapy. Cognitive exercises are delivered with NeuropsychOnline and administered by a trained coach.

    Also known as: CRT

  • BehavioralSham cognitive remediation therapy

    An active comparator for cognitive remediation therapy, delivered with quizzes collected from Sporcle.com.

    Also known as: sham CRT

06

What researchers measure

Primary outcomes

  1. Functional connectivity with the prefrontal cortex

    Participants will be directed to keep their eyes open and loosely fixed on a plus sign on the screen in front of them for 5 minutes while EEG is recorded. Resting data will be cleaned, processed, and transformed to 4 frequency band values: delta/theta, alpha, beta, and gamma. Frequency data will be converted to connectivity values using weighted phase lag index (wPLI). Average connectivity of all sensors with the prefrontal sensor F3 will be calculated and compared between timepoints.

    Time frame: Pre-intervention to post-intervention at 2-weeks

Secondary outcomes

  1. Brief Assessment of Cognition Digit Sequencing (Working Memory)

    Participants will arrange random number strings in ascending order during the Brief Assessment of Cognition. This score, which indexes working memory is called Digit Sequencing and will be z-scored according to published norms and compared between timepoints.

    Time frame: Pre-intervention to post-intervention at 2-weeks

Other outcomes

  1. Brief Assessment of Cognition subdomains

    Participants will complete the Brief Assessment of Cognition, which includes tasks indexing psychomotor and visual processing speed, lexical access, attention and processing speed, and executive functioning, called Token Motor, Verbal Fluency, Symbol Coding, and Tower of London, respectively. These subdomain scores will be normed and compared between timepoints.

    Time frame: Pre-intervention to post-intervention at 2-weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Only IPD used in the results publication will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.

Of 760 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 11 months is below that.

Counting every sponsor, half of 773 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940712
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Rebekah L Trotti, PhD
Contact
rtrotti@bidmc.harvard.edu
617-754-1262
Brendan Stiltner, BS
Contact
bstiltne@bidmc.harvard.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion